Serum/plasma CRAG+ individuals can then be effectively preemptively treated before development of symptomatic CM [4], improving long-term outcomes in a likely cost-effective manner [8], [26], [27]. The gene discussed is AGAP3; the disease is cutaneous mastocytosis.